International Studies
The NMDA receptor antagonist memantine demonstrates clinically significant efficacy in patients with moderately to severe Alzheimer's disease. Merz has received approval for AXURA for the treatment of moderately severe and severe Alzheimer's disease from the European Commission and the Food and Drug Administration (FDA) in the USA. Marketing authorization is based primarily on these two international placebo-controlled studies:
 |
Memantine in moderate-to-severe Alzheimer's disease Reisberg B et al. (2003). New England Journal of Medicine, 348 (14): 1333-41. [ More detailed data ] [ Abstract ] |
 |
Memantine in severe dementia: results of the M-BEST Study Winblad B, Poritis N (1999). Int J Geriatr Psychiatry, 14 (2): 135-46. [ More detailed data ] [ Abstract ] |
